MedTrace Logo

Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection

NCT00668382 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2013-05-15

Study results available
· View outcomes & findings →

Summary

This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.

Conditions

  • Neoplasm Metastases

Interventions

BIOLOGICAL

Alpha-Gal Glycosphingolipid

Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity

Sponsors & Collaborators

  • University of Massachusetts, Worcester

    lead OTHER

Principal Investigators

  • Giles Whalen, MD · University of Massachusetts, Worcester

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668382 on ClinicalTrials.gov